



Luzu[®] (luliconazole) – Expanded indication

- On February 20, 2018, the FDA approved Valeant's **Luzu (luliconazole)** cream, for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms *Trichophyton rubrum* and *Epidermophyton floccosum*.
 - Previously, Luzu was approved only for patients 18 years of age or older for the same indication.
- Data to support the expanded indication for Luzu was based on a vehicle-controlled study of 75 patients aged 2 to < 18 years old with a diagnosis of tinea corporis. Patients were treated for 7 days.
 - Complete clearance (clinical cure and mycological cure) three weeks after treatment was achieved in 71% of the Luzu-treated patients vs. 36% of the vehicle-treated patients.
 - In addition, the safety and effectiveness of Luzu in pediatric patients 12 to < 18 years of age with tinea pedis and tinea cruris have been established by evidence from well-controlled trials in adult and pediatric patients and a pharmacokinetic study in pediatric patients.
- The recommended dosage of Luzu is to apply the cream to the affected area and approximately 1 inch of the immediate surrounding area(s) once daily.
 - Interdigital tinea pedis should be treated for two weeks.
 - Tinea cruris or tinea corporis should be treated for one week.
 - Luzu is for topical use only. Luzu is not for ophthalmic, oral, or intravaginal use.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.